Login to Your Account

Deals Roundup

Pharmacyclics Buys Celera Compounds For Up To $150M

By Karen Pihl-Carey

Tuesday, April 11, 2006
Three months after announcing a restructuring plan to focus only on molecular diagnostics and proteomics, Celera Genomics Group sold several small-molecule drug candidates to Pharmacyclics Inc. in a deal worth up to $150 million in up-front, equity and milestone payments. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription